Assuntos
Anti-Hipertensivos/farmacologia , Cálcio/metabolismo , Hipertensão/complicações , Osteoporose/complicações , Antagonistas Adrenérgicos beta/farmacologia , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Idoso , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Animais , Anti-Hipertensivos/uso terapêutico , Densidade Óssea , Bloqueadores dos Canais de Cálcio/farmacologia , Bloqueadores dos Canais de Cálcio/uso terapêutico , Cálcio da Dieta/administração & dosagem , Ensaios Clínicos como Assunto , Diuréticos/farmacologia , Diuréticos/uso terapêutico , Exercício Físico , Espaço Extracelular/metabolismo , Feminino , Humanos , Hipertensão/metabolismo , Hipertensão/terapia , Masculino , Osteoporose/etiologia , Osteoporose/prevenção & controle , Ratos , Ratos Endogâmicos SHRRESUMO
The aim of this study was to generate standard curves for bone mineral density (BMD) in a Spanish population using dual-energy X-ray absorptiometry (DXA), at both lumbar spine and femoral neck sites. The total sample size was 2442 subjects of both sexes aged 20-80 years, stratified according to survival rates, demographic distribution by local regions and sex ratio in the Spanish population. Subjects with suspected conditions affecting bone metabolism or receiving any treatment affecting bone mineralization were excluded. The study was carried out in 14 hospitals and bone density measurements were performed, using a QDR/ 1000 Hologic device. In the female population, the highest value for lumbar spine BMD was found within the 30-39 years age group, being significantly lower after the age of 49 years. In the male population, the highest values for lumbar spine BMD are found one decade earlier than in the female population and become significantly lower after the age of 69 years. The highest values for femoral neck BMD in men and women was found in the 20-29 year age group. Values for femoral neck BMD in the female population become statistically lower after the age of 49 years, while in the male population this effect was seen after the age of 69 years. Values for femoral neck BMD were higher in men than women at all ages.
Assuntos
Densidade Óssea , Colo do Fêmur/fisiologia , Vértebras Lombares/fisiologia , Absorciometria de Fóton , Adulto , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Variações Dependentes do Observador , Valores de Referência , Reprodutibilidade dos Testes , Caracteres Sexuais , EspanhaAssuntos
Azitromicina , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Azitromicina/farmacologia , Azitromicina/uso terapêutico , Bactérias/efeitos dos fármacos , Infecções Bacterianas/tratamento farmacológico , Disponibilidade Biológica , Criança , Pré-Escolar , Interações Medicamentosas , Resistência Microbiana a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ribossomos/efeitos dos fármacos , Treponema pallidum/efeitos dos fármacosRESUMO
A controlled double-blind clinical trial was performed comparing therapeutic efficacy of hidrosmin versus diosmin in patients suffering from chronic venous insufficiency with varicose symptomatology in the inferior limbs. Ten patients were treated with hidrosmin and other 10 with diosmin randomly. The controls carried out during the trial were as follows; basal control before the beginning of the trial and therapeutic controls on days 15, 30, 60 and 90 of the study. With that aim clinical examinations and different explorations were performed: physical exam, phlebography, electrocardiogram, ophthalmological examination and biochemical analyses (hemogram, globular sedimentation rate, platelet counts, etc.). The clinical therapeutic efficacy of hidrosmin in the treatment of chronic venous insufficiency of inferior limbs was superior to the diosmin in most of the studied parameters even though a lower posology was employed. From a clinical point of view the clinical improvement in the subjective symptomatology (heaviness, local tenderness, cramps, paresthesias, etc.) was very superior to the one obtained with the objective signs (phlebography, skin trophism, evolution of the edema, etc.). No significative adverse reactions appeared.
Assuntos
Diosmina/análogos & derivados , Diosmina/uso terapêutico , Edema/tratamento farmacológico , Síndrome Pós-Flebítica/tratamento farmacológico , Varizes/tratamento farmacológico , Insuficiência Venosa/tratamento farmacológico , Adulto , Idoso , Doença Crônica , Diosmina/efeitos adversos , Método Duplo-Cego , Tolerância a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The articles published in 1985 in 9 journals (3 of Internal Medicine, 3 of Pediatrics and 3 of Clinical Pharmacology) are revised with the purpose of studying: a) Number of clinical trials published. b) Number of clinical trials published accomplished in children. Among the 533 trials published, 102 were done in children. The type of trial done is studied based on the methodology used, if healthy volunteers are included, if pharmacokinetics studies were done, the ages of the subjects, the number of subjects included, the sex and the way of obtaining the informed consent.
Assuntos
Ensaios Clínicos como Assunto/métodos , Tratamento Farmacológico , Pediatria , Adolescente , Criança , Pré-Escolar , Estudos de Avaliação como Assunto , Feminino , Humanos , Lactente , Recém-Nascido , MasculinoAssuntos
Antiulcerosos/uso terapêutico , Úlcera Péptica/tratamento farmacológico , Alumínio/uso terapêutico , Antiácidos/uso terapêutico , Benzodiazepinonas/uso terapêutico , Carbenoxolona/uso terapêutico , Mucosa Gástrica/efeitos dos fármacos , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Humanos , Morfolinas/uso terapêutico , Parassimpatolíticos/uso terapêutico , Pirenzepina , Prostaglandinas/uso terapêutico , SucralfatoAssuntos
Antiarrítmicos/farmacologia , Potenciais de Ação/efeitos dos fármacos , Antagonistas Adrenérgicos beta/farmacologia , Antiarrítmicos/classificação , Bloqueadores dos Canais de Cálcio/farmacologia , Sistema de Condução Cardíaco/efeitos dos fármacos , Humanos , Canais Iônicos/efeitos dos fármacosAssuntos
Amicacina/farmacologia , Bactérias/efeitos dos fármacos , Gentamicinas/farmacologia , Canamicina/análogos & derivados , Tobramicina/farmacologia , Amicacina/efeitos adversos , Amicacina/metabolismo , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/metabolismo , Interações Medicamentosas , Resistência Microbiana a Medicamentos , Orelha/efeitos dos fármacos , Gentamicinas/efeitos adversos , Gentamicinas/metabolismo , Humanos , Rim/efeitos dos fármacos , Tobramicina/efeitos adversos , Tobramicina/metabolismoAssuntos
Anfotericina B/farmacologia , Citosina/análogos & derivados , Dermatomicoses/tratamento farmacológico , Flucitosina/farmacologia , Imidazóis/farmacologia , Anfotericina B/efeitos adversos , Interações Medicamentosas , Flucitosina/efeitos adversos , Humanos , Imidazóis/efeitos adversos , Rim/efeitos dos fármacosRESUMO
130 patients with edema as the sequel of a traumatic incident were selected for this study, 43 patients were treated with 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for one week, 44 patients received 600 mg oxyphenbutazone per day and 43 patients received placebo. Medication could be terminated if edema and pain disappeared or if deterioration or intolerance occurred. Extent of edema and degree of pain were assessed at entry into the study and on days 3, 5 and 8. Efficacy was assessed by the number of days elapsed before definite reduction and/or complete disappearance of edema and by the decrease and disappearance of pain. Meclofenamate sodium proved to be significantly superior to placebo in the treatment of patients with post-traumatic edema and post-traumatic pain. Reduction and disappearance of edema and cessation of pain occurred significantly more promptly in patients receiving meclofenamate sodium than in those receiving placebo. Although no statistically significant differences were observed between meclofenamate sodium and oxyphenbutazone, the results suggested that meclofenamate sodium might be clinically superior. Meclofenamate sodium was well tolerated.